DOCSLIB.ORG

Pyrrolizidine Alkai,Oids

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

This report contains the collective views of an in- ternational group of experts and does not necessarily represent the decisions or the stated policy of the United Nations Environment Programme, the Interna- tional Labour Organisation, or the World Health Organization Environmental Health Criteria 80 PYRROLIZIDINE ALKAI,OIDS Published under the joint sponsorshipof the United Nations Environment Programme, the International Labour Organisation, and the World Health Organization World Health Organization Geneva, 1988 The lnternational Programme on Chemical Safety (IPCS) is a joint venture of the United Nations Environment Programme, the International Labour Organisa- tion, and the World Health Organization. The main objective of the IPCS is to carry out and disseminateevaluations of the effects of chemicals on human health and the quality ofthe environment. Supporting activities include the development of epidemiblogical,experimental laboratory, and risk-assessmentmethods that could produce irtternationally comparable results, and the development of manpower in the field of toxicology. Other activities carried out by IPCS include the develop- ment of know-how for coping with chemical accidents,coordination of laboratory testing and epidemiological studies, and promotion of researchon the mechanisms of the biological action of chemicals. rsBN 92 4 t54280 2 @World Health Organization 1988 Publications of the World Health Organization enjoy copyright protection in accordancewith the provisions of Protocol 2 of the Universal Copyright Conven- tion. For rights of reproduction or translation of WHO publications, in part or in toto, application should be made to the Office of Publications, World Health Organization, Geneva,Switzerland, The World Health Organization welcomessuch applications. The designationsemployed and the presentation of the material in this publica- tion do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommendedby the World Health Organiza- tion in preferenceto others of a similar nature that are not mentioned. Errors and omissions excepted,the names of proprietary products are distinguished by initial capital letters. rssN0250-863X PRINTED IN FINLAND DASS_VAMMALA-5500 RIA FOR PYRROLIZIDINE ALKALOIDS PREFACE L2 INTRODUCTION- PYRROLI NE ALKALOIDS AND ITI'MANHEALTI{ . 13 1. ST'MMARY.A,ND 19 1.1 Sumary L9 t.2 Sources'and c alstructure... 19 1.3 Mechanisms and tures of toxicity 20 t.4 Effects on man 22 1.4.1 Nature extent of health risks . 22 1.5 Methods for tion . 24 1.6 Reconurendat ions 24 1.6.1 General tions . 24 t.6.2 tions for research 25 2. PROPERTIESAND ANAL METHODS 27 2.L ChemicaL struc re and properties 27 2.2 AnaLvtical me 32 2.2.L ExtractidnExtract.t-on 33 2.2.L.L Pl-ant tissue . 33 2.2.1.2 Biological- ffluids l-uids and tissues 33 2.2.2 Analysis for pyrrolizidine aLkaloids 33 2.2.2.1 jthin-Layer chromatography (TLC). 33 2.2.2.2 High-performance 1-iquid chromatography (HPLC) 34 2.2.2.3 Gas chromatography (GC) and mass spectrometry (MS) . 34 2 .2.2.4 Nucl-ear magnetic resonance (NMR) spectrometry . 35 2.2.2.5 The Ehrlich reaction 35 2.2.2.6 Indicator dyes . 36 2.2.2.7 DirecE weighing 36 2.3 Determinationo metabolites in animal tissues . 37 J. SOURCESAND PATHWAYSOF EXPOSUPG 3.1 Hepatotoxic pyrfolizidine alkaloids and their sources . 38 3.2 Pneumotoxic and other toxic pyrrolizidine alkaloids I -4- Page 3.3 Pathvays of exposure 42 3.3.1 Contamination of staple food crops 43 3.3.2 Herbal infusions 43 3.3.3 Use of PA-containing plants as food 47 3.3.4 Contaminated honey 50 3.3.5 Mitk 51 3.3.6 Meat 54 3.3.7 Use of PAs as chemottrerapeutic agents for cancer 54 4. METABOLISU )) 4.L Absorption, excretion, and tissue distribution . 55 4.l.L Absorption 55 4.I.2 Excretion and distribution 55 4.2 Metabolic routes 58 4.2.L Hydrolysis .. .58 4.2.2 N-oxidation 59 4.2.3 donversion to pyrrolic metabolites 59 4.3 Effects of treatments affecting metaboLism . 61 4.4 other factors affecting rnetabolism . 63 4.5 Other metabolic routes 63 4.6 Metabolism of pyrrolizidine N-oxides . 64 4.7 Metabolism in man . 64 5. MECHANISI.{SOF TOXICIIY AND OTHER BIOLOGICAT ACTIONS . 65 5.1 Metabolites responsibLe for toxicity . 65 5.l.L MetaboLic basis of toxicity 65 5.I.2 Isolation of pyrrolic rnetabolites . 66 5.1.3 Chemical aspects of pyrrolic metabolites . 66 5.1.3.1 Preparation 66 5.1.3.2 Chemistrv associated with toxic actions 67 5.L.4 Possible further metaboLites 68 5.2 Toxic actions of pyrrolic netabolites 69 5.2.L Aninals 69 5.2.t.L Pyrrolic esters (dehydro- alkal-oids ) 69 5.2.L.2 Pyrrolic alcohoLs (dehydro- necines) .....70 5.2.2 CeLl culturea . 7| 5.2.3 Possible participation of membrane lipid peroxidation.. ... .72 5.3 ChenicaL and metabolic factors affecting toxicity .....72 5.3.1 Structural featureg of a toxic alkaloid . 72 -5- Page 5.3.2 Activat and toxication 73 5.3.3 Factors ffect the toxicity of active rnetaboLi ea. 74 5.3.3.1 React ity of the metabolite . 74 5.3.3.2 The r of reactive groups 74 5.4 Metabolites 1a with the biological actions of pyrrolizid alka ids.. 75 5 .4.L Acute h city 75 5.4.2 Chronic totpxicity 75 5.4.3 Pneumoto:iicity 76 r tissues 76 77 itv.. 77 5.) t of pyrrol-izidine 78 5.5.1 Modified diets 78 5.5.2 Pre-treadment t enhance the detoxication of activd metat lites . 79 5.5.3 Other trdatment 80 6. EFFECTSoN ANIMALS J . 81 6.1 Patterns of disdase ca by different plant genera and of or{gan in lvement in different 81 tbreaks in farm animals . 81 84 l.es 87 1-ver B7 hepatotoxicity of t PAs and their N-oxides . 87 affecting hepatoEoxicity . 87 ffects 92 sm of toxic acEion 97 effects 98 6.4.2 ungs 103 ffects . 105 effects . 110 sms of toxic action . rL4 6.4.3 entral nervous svstemoJ o LLut L2L 6.4.4 organs . L2I 6.4.5 ..L24 6,4.6 ..L24 6.4.7 ..L26 damage ....129 6.4.8 .rt"i.ia"::::::::il; -5- Page 6.4.8.2 PlantmateriaLs ....L67 6.4.8.3 Pvrrolizidine alkal-oid metabolites aid analogous synthetic compounds ... 171 6.4.8.4 MoLecular structure and carcinogenicactivity ..173 6.4.9 Antimitoticactivity ...L74 6.4.10 Imunosuppression .. ..L75 6.4.11 Effects on mineral metabolism . L75 6.4.L2 Methods for the assessment of chronic hepatotoxicity and pnetmotoxicity . 176 6.5 EffectsonwiLd-life... ....L77 6.5.1 Deer ...L77 6.5.2 Fish.. ..L77 6.5.3 Insects ..178 7. EFFECTSON MAN .. .L79 7.I Clinical features of veno-occlusive disease (voD) L79 7.2 Salient pathoLogical features of veno- occlusivedisease . 181 7.3 Human cage reports of veno-occlusive disease . 183 7.4 VoD end cirrhosis of the liver . 201 7.5 Differences between VOD and Indianchildhoodcirrhosis (Icc) . 2O3 7.6 Chronic lung disease . .204 7.7 Trichodesma poisoning . 2O5 7.8 Eaiffiil?frIp betlreen dose leveL and toxic effects . ..206 7.9 Pyrrolizidine alkaloids as a chemotherapeutic agentforcancer .;.. .....2L3 7.10 Prevention of poisoning in man . 2L4 8. BIOLOGICAL CONTROL 9. EVALUATION OF ITI'MANIIEALTH RISKS AND EFFECTS ON THE ENVIRONMENT . 2L7 9.1 lluman exposure conditioirs . .2L7 9.1.1 Reported sources of hr:man exposure . 2L7 9.1.2 Plant species invoLved . 2L7 9.1.3 Modes and pathways of exposure . 2I8 9.1.3.,1 Contamination of grain crops . 2L8 9 .L.3 .2 lterbaL medicines . 218 9.L.3.3 PA-containing pLants used as food andbeverages ..2L9 9.1.3.4 Other food contaminated by PAs . 2L9 -1- Page g.L.4 Levels of intake 220 9.2 Acute effects of exposure 222 9.2.I Acute livdr disease 222 9 .3 Chronic dffects <]rfexposure 223 9.3.1 Cd.rrhosis of the liver 223 9.3.2 Mutagenic{ty and teratogenicity 223 9.3.3 Cancer of the liver . 223 9.3.4 Effeits o{t other organs 224 9.4 Effects on the edvironment 225 9.4.L Agricultufe 225 226 9.4.3 Iosects 226 9.4.4 Soil and ter .,226 227 APPENDIXI. PYRROLIZID ALKALOIDS AND TIIEIR PLANT APPENDIXII. TABIE 1. PI,ANTS HEPATOTOXICPYRROLIZIDINE ALKALOIDS 303 TABLE 2. PI,ANTS INING KNOWNALKALOIDS THAT ARE NON-IIEPA C (AI,IINOALCOHOLSAND ESTERS) . 337 -8- MIO TASK GROUPON PYRROLIZIDINE ALKALOIDS Members Professor M.S. AbduLLahodjaeva, Uzbek Republican Centre for Pathological Anatomy, Tashkent State Medical Institute, Tashkent, USSR Dr C.C.J. Culvenor, Comronwealth Scientific and Industrial Research Organization, Division of Anirnal llealth, Parkville, Victoria, AustraLia (Cttrir*") Professor P.P. Dykun, Department of Biophysica, Petrov Research Institute of Oncology, Leningrad, USSR Dr H.N.B. Gojalan, University of Nairobi, Department of Botany, Nairobi, Kenya Dr R.J. ttuxtable; Department of Pharmacology, University of Arizona, Tucson, Arizona, USA Dr A.R. Mattocks, MRCToxicology Unit, Medical Research Council Laboratories, Carshalton, Surrey, United Kingdom Dr V. Murray, NationaL Poisons Information Service, New Cross Hospital, London, United Kiogdom Dr B. Snith, Division of Food Regulatory Affairs, Food Directorate, HeaLth Protection Branch, Tunneyrs Pasture, Ottawa, Canada Professor It.D. Tandon, NationaL Academy of Medical Sciences (India), Ansari Nagar, New DeLhi, India (Chairnan) Academician F.YU.
Recommended publications
  • Report of the Advisory Group to Recommend Priorities for the IARC Monographs During 2020–2024

    Report of the Advisory Group to Recommend Priorities for the IARC Monographs During 2020–2024

    IARC Monographs on the Identification of Carcinogenic Hazards to Humans Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 CONTENTS Introduction ................................................................................................................................... 1 Acetaldehyde (CAS No. 75-07-0) ................................................................................................. 3 Acrolein (CAS No. 107-02-8) ....................................................................................................... 4 Acrylamide (CAS No. 79-06-1) .................................................................................................... 5 Acrylonitrile (CAS No. 107-13-1) ................................................................................................ 6 Aflatoxins (CAS No. 1402-68-2) .................................................................................................. 8 Air pollutants and underlying mechanisms for breast cancer ....................................................... 9 Airborne gram-negative bacterial endotoxins ............................................................................. 10 Alachlor (chloroacetanilide herbicide) (CAS No. 15972-60-8) .................................................. 10 Aluminium (CAS No. 7429-90-5) .............................................................................................. 11
  • Clinical Biochemistry of Hepatotoxicity

    Clinical Biochemistry of Hepatotoxicity

    linica f C l To o x l ic a o n r l o u g Singh, J Clinic Toxicol 2011, S:4 o y J Journal of Clinical Toxicology DOI: 10.4172/2161-0495.S4-001 ISSN: 2161-0495 ReviewResearch Article Article OpenOpen Access Access Clinical Biochemistry of Hepatotoxicity Anita Singh1, Tej K Bhat2 and Om P Sharma2* 1CSK Himachal Pradesh, Krishi Vishva Vidyalaya, Palampur (HP) 176 062, India 2Biochemistry Laboratory, Indian Veterinary Research Institute, Regional Station, Palampur (HP) 176 061, India Abstract Liver plays a central role in the metabolism and excretion of xenobiotics which makes it highly susceptible to their adverse and toxic effects. Liver injury caused by various toxic chemicals or their reactive metabolites [hepatotoxicants) is known as hepatotoxicity. The present review describes the biotransformation of hepatotoxicants and various models used to study hepatotoxicity. It provides an overview of pathological and biochemical mechanism involved during hepatotoxicity together with alteration of clinical biochemistry during liver injury. The review has been supported by a list of important hepatotoxicants as well as common hepatoprotective herbs. Keywords: Hepatotoxicity; Hepatotoxicant; In Vivo models; In Vitro production of bile thus leading to the body’s inability to flush out the models; Pathology; Alanine aminotransferase; Alkaline phosphatase; chemicals through waste. Smooth endoplasmic reticulum of the liver is Bilirubin; Hepatoprotective the principal ‘metabolic clearing house’ for both endogenous chemicals like cholesterol, steroid hormones, fatty acids and proteins, and Introduction exogenous substances like drugs and alcohol. The central role played by liver in the clearance and transformation of chemicals exposes it to Hepatotoxicity refers to liver dysfunction or liver damage that is toxic injury [4].
  • National Center for Toxicological Research

    National Center for Toxicological Research

    National Center for Toxicological Research Annual Report Research Accomplishments and Plans FY 2015 – FY 2016 Page 0 of 193 Table of Contents Preface – William Slikker, Jr., Ph.D. ................................................................................... 3 NCTR Vision ......................................................................................................................... 7 NCTR Mission ...................................................................................................................... 7 NCTR Strategic Plan ............................................................................................................ 7 NCTR Organizational Structure .......................................................................................... 8 NCTR Location and Facilities .............................................................................................. 9 NCTR Advances Research Through Outreach and Collaboration ................................... 10 NCTR Global Outreach and Training Activities ............................................................... 12 Global Summit on Regulatory Science .................................................................................................12 Training Activities .................................................................................................................................14 NCTR Scientists – Leaders in the Research Community .................................................. 15 Science Advisory Board ...................................................................................................
  • CHEMICAL PRODUCTS CORPORATION April 20, 2018 Via

    CHEMICAL PRODUCTS CORPORATION April 20, 2018 Via

    CHEMICAL PRODUCTS CORPORATION CARTERSVILLE, GEORGIA 30120 POST OFFICE BOX 2470 TELEPHONE 770-382-2144 FAX 770-386-6053 April 20, 2018 Via Certified Mail and Electronic Mail ([email protected]) USEPA Headquarters William Jefferson Clinton Federal Building 1200 Pennsylvania Avenue, NW Mail Code: 2821T Washington, DC 20460 Subject: Information Quality Guidelines (IQG) identifier: RFC #17003 Additional Information demonstrating that National Toxicology Program Technical Report 494 should not be the basis for provisional screening values presented in Appendix A of “Provisional Peer-Reviewed Toxicity Values for 9,10- Anthraquinone (CASRN 84-65-1)”, EPA/690/R-11/007F, Final 2-17-2011 or the screening levels for “Anthraquinone, 9,10-” in EPA’s Regional Screening Level Tables Dear Sir or Madam: This letter contains additional information to supplement the Request for Correction submitted by Chemical Products Corporation (CPC) on April 6, 2018, assigned Information Quality Guidelines Identifier RFC #17003. The contents of this letter provide yet another sufficient reason to conclude that the National Toxicology Program (NTP) peer review panel which accepted the conclusions presented in NTP Technical Report 494 (TR-494) were not presented accurate information, thus, the peer review panel was unable to render a sound scientific judgment regarding the conclusions presented in TR-494. The peer review of TR- 494 does not meet the “sound and objective scientific practices” REQUEST FOR CORRECTION SUBMITTED BY CHEMICAL PRODUCTS CORPORATION Additional Information IQG identifier: RFC #17003 Page 2 of 5 April 20, 2018 requirement contained in the EPA Guidelines and should not be accepted by EPA as a valid peer review.
  • TOX-27: Riddelliine (CASRN 23246-96-0)

    TOX-27: Riddelliine (CASRN 23246-96-0)

    National Toxicology Program Toxicity Report Series Number 27 NTP Technical Report on Toxicity Studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344/N Rats and B6C3F1 Mice Po C. Chan, PhD, Study Scientist National Toxicology Program Post Office Box 12233 Research Triangle Park, NC 27709 NIH Publication 94-3350 December 1993 United States Department of Health and Human Services Public Health Service National Institutes of Health Note to the Reader The National Toxicology Program (NTP) is made up of four charter agencies of the United States Department of Health and Human Services (DHHS): • the National Cancer Institute (NCI) of the National Institutes of Health; • the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health; • the National Center for Toxicological Research (NCTR) of the Food and Drug Administration; and • the National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control. In July 1981, the Carcinogenesis Bioassay Testing Program was transferred from NCI to NIEHS. NTP coordinates the relevant Public Health Service programs, staff, and resources that are concerned with basic and applied research and with biological assay development and validation. NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease. To carry out its mission, NTP designs and conducts studies to characterize and evaluate the toxicologic potential of selected chemicals in laboratory animals (usually two species, rats and mice). Chemicals selected for NTP toxicology studies are chosen primarily on the bases of human exposure, level of production, and chemical structure.
  • D. SENECIO SPECIES and RIDDELLIINE 1. Exposure Data

    D. SENECIO SPECIES and RIDDELLIINE 1. Exposure Data

    D. SENECIO SPECIES AND RIDDELLIINE 1. Exposure Data 1.1 Origin, type and botanical data (Molyneux et al., 1991) Senecio riddellii (Asteraceae) (Riddell groundsel) is a grey-white half-shrub, 30–90 cm tall with pinnatifid and relatively hairless leaves, revealing its bright green leaf colour. It has bright yellow flowers on the stems at about the same height above the ground. This gives the plant a flat-topped appearance when in bloom. It produces flowers in late summer to early autumn and dies back to ground level after the first frost. It grows in dry, sandy soils and its roots are long and about as thick as a lead pencil. Senecio longilobus (also known as woolly groundsel and thread-leaf groundsel) is a shrubby, erect, branched, leafy plant, 30–60 cm tall. It has narrowly linear leaves which are thick, white, and occasionally pinnately lobed, up to 10 cm long. The composite yellow flower heads contain numerous clusters. In North America, this is a common plant with a range extending from Colorado to Utah, south to Texas and Mexico (Kingsbury, 1964). 1.2 Use The ‘bush tea’ used in Jamaica to treat children for a cold an a herbal tea that is popular in the south-west USA, gordolobo yerba, may contain riddelliine (Stillman et al., 1977a; Huxtable, 1980; National Toxicology Program, 2002). 1.3 Chemical constituents The plants (ragworts) from which riddelliine and other pyrrolizidine alkaloids are isolated are found in the rangelands of the western USA. Cattle, horses and, less commonly, sheep that ingest these plants can succumb to their toxic effects (called pyrro- lizidine alkaloidosis).
  • 6) Hepatotoxic Drugs

    6) Hepatotoxic Drugs

    ILOs § Define the role of liver in drug detoxification § Discuss the types (patterns) of hepatotoxicity § Classify hepatotoxins § Explain how a drug can inflict hepatotoxicity § State the pathological consequences of hepatic injury § Contrast the various clinical presentation of hepatotoxicity § Enlist the possible treatment PHYSIOLOGICAL has multiple functions (>5000) è can be categorized into: 1. Regulation, synthesis & secretion. èutilization of glucose, lipids & proteins + bile for digesting fats. 2. Storage. è Glucose (as glycogen), fat soluble vitamins (A, D, E & K) & minerals 3. Purification, transformation & clearance è of endogenous (steroid hormones, cholesterol, FA, & proteins..) & exogenous (drugs, toxins, herbs…etc ) chemicals. Human body identifies almost all drugs as foreign substances i.e. XENOBIOTIC Has to get rid of them "METABOLIC CLEARING HOUSE" PHARMACOLOGICAL HEPATOTOXIC DRUGS Subjects drugs to chemical transformation (METABOLISM) è to become inactive & easily excreted. Since most drugs are lipophilic è they are changed into hydrophilic water soluble products è suitable for elimination through the bile or urine Such metabolic transformation usually occur in 2 PHASES: Phase 1 reactions Yields intermediates è Oxidation, Reduction, polar, transient, usually highly reactive è Hydrolysis, Hydration far more toxic than parent substrates è Catalyzed by CYT P-450 may result in liver injury Drug-Induced Liver Injury (DILI) Phase 2 reactions Yields products of increased solubility Conjugation with a moiety If of high molecular weight è (acetate, a.a., glutathione, excreted in bile glucuronic a., sulfate ) If of low molecular weight è to blood è excreted in urine Hepatotoxicity è Is the Leading cause of ADRs Injury / damage of the liver è Caused by exposure to a drug è Inflict varying impairment in liver functions è Manifests clinically a long range è hepatitis ðfailure Inflammation ðApoptosis ð Necrosis Why the liver is the major site of ADRs ? It is the first organ to come in contact with the drug after absorption from the GIT.
  • Pyrrolizidine Alkaloids: Biosynthesis, Biological Activities and Occurrence in Crop Plants

    Pyrrolizidine Alkaloids: Biosynthesis, Biological Activities and Occurrence in Crop Plants

    molecules Review Pyrrolizidine Alkaloids: Biosynthesis, Biological Activities and Occurrence in Crop Plants Sebastian Schramm, Nikolai Köhler and Wilfried Rozhon * Biotechnology of Horticultural Crops, TUM School of Life Sciences Weihenstephan, Technical University of Munich, Liesel-Beckmann-Straße 1, 85354 Freising, Germany; [email protected] (S.S.); [email protected] (N.K.) * Correspondence: [email protected]; Tel.: +49-8161-71-2023 Academic Editor: John C. D’Auria Received: 20 December 2018; Accepted: 29 January 2019; Published: 30 January 2019 Abstract: Pyrrolizidine alkaloids (PAs) are heterocyclic secondary metabolites with a typical pyrrolizidine motif predominantly produced by plants as defense chemicals against herbivores. They display a wide structural diversity and occur in a vast number of species with novel structures and occurrences continuously being discovered. These alkaloids exhibit strong hepatotoxic, genotoxic, cytotoxic, tumorigenic, and neurotoxic activities, and thereby pose a serious threat to the health of humans since they are known contaminants of foods including grain, milk, honey, and eggs, as well as plant derived pharmaceuticals and food supplements. Livestock and fodder can be affected due to PA-containing plants on pastures and fields. Despite their importance as toxic contaminants of agricultural products, there is limited knowledge about their biosynthesis. While the intermediates were well defined by feeding experiments, only one enzyme involved in PA biosynthesis has been characterized so far, the homospermidine synthase catalyzing the first committed step in PA biosynthesis. This review gives an overview about structural diversity of PAs, biosynthetic pathways of necine base, and necic acid formation and how PA accumulation is regulated. Furthermore, we discuss their role in plant ecology and their modes of toxicity towards humans and animals.
  • Drug and Alcohol Induced Hepatotoxicity

    Drug and Alcohol Induced Hepatotoxicity

    From The Department of Physiology and Pharmacology, Section of Pharmacogenetics Karolinska Institutet, Stockholm, Sweden DRUG AND ALCOHOL INDUCED HEPATOTOXICITY Angelica Butura Stockholm 2008 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. © Angelica Butura, 2008 ISBN 978-91-7409-055-0 To my parents for always believing in me ABSTRACT Drug induced hepatotoxicity is the most common reason cited for withdrawal of already approved drugs from the market and accounts for more than 50 percent of cases of acute liver failure in the United States. Ethanol (EtOH) causes a further substantial amount of liver insufficiencies world wide. The current thesis was focused on the mechanisms behind hepatotoxicity caused by these agents. Using a rat in vivo model for alcoholic liver disease (ALD) it was found that cytokine and chemokine levels in blood accompanied the fluctuating levels of blood EtOH, indicating that they are directly influenced by absolute EtOH concentration. During the early phases of ALD in this model, a strong initial Th1 response was observed as revealed by increased levels of cytokine as well as transcription factor mRNAs, followed by a downregulation, whereas Th2 response was decreased by EtOH over the entire treatment period of four weeks. We found that supplementation with the antioxidant NAC to ethanol treated animals decreases severity of liver damage and somewhat decreases initial inflammatory response mediated by TNFα. NAC also diminished the ethanol-induced formation of protein adducts of lipid peroxidation products like MDA and HNE. Also, the formation of antibodies against neo-antigens formed by MDA, HNE and HER protein adducts was lowered.
  • Public Statement on Contamination of Herbal Medicinal Products

    Public Statement on Contamination of Herbal Medicinal Products

    31 May 2016 EMA/HMPC/328782/2016 Committee on Herbal Medicinal Products (HMPC) Public statement on contamination of herbal medicinal products/traditional herbal medicinal products1 with pyrrolizidine alkaloids Transitional recommendations for risk management and quality control Discussion in Working Party on European Union Monographs and April 2016 European Union List (MLWP) Adoption by Committee on Herbal Medicinal Products (HMPC) 31 May 2016 Keywords Herbal medicinal products; HMPC; pyrrolizidine alkaloids; transitional recommendations for risk management and quality control 1 Throughout the document the term Herbal Medicinal Products (HMPs) includes Traditional Herbal Medicinal Products as defined in Dir. 2001/83/EC 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ......................................................................................... 2 1. Background ............................................................................................. 3 2. Brief review of toxicological data ............................................................ 4 2.1. Acute and subchronic toxicity of PAs ....................................................................... 4 2.2. Genotoxicity .......................................................................................................
  • The Role of Oxidative Stress in Α-Amanitin-Induced Hepatotoxicity in an Experimental Mouse Model

    The Role of Oxidative Stress in Α-Amanitin-Induced Hepatotoxicity in an Experimental Mouse Model

    Turkish Journal of Medical Sciences Turk J Med Sci (2017) 47: 318-325 http://journals.tubitak.gov.tr/medical/ © TÜBİTAK Research Article doi:10.3906/sag-1503-163 The role of oxidative stress in α-amanitin-induced hepatotoxicity in an experimental mouse model 1 1, 2 1 3 1 Zerrin Defne DÜNDAR , Mehmet ERGİN *, İbrahim KILINÇ , Tamer ÇOLAK , Pembe OLTULU , Başar CANDER 1 Department of Emergency Medicine, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey 2 Department of Biochemistry, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey 3 Department of Medical Pathology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey Received: 31.03.2015 Accepted/Published Online: 11.01.2016 Final Version: 27.02.2017 Background/aim: This study aimed to evaluate oxidative stress markers of liver tissue in a mouse α-amanitin poisoning model with three different toxin levels. Materials and methods: The mice were randomly divided into Group 1 (control), Group 2 (0.2 mg/kg), Group 3 (0.6 mg/kg), and Group 4 (1.0 mg/kg). The toxin was injected intraperitoneally and 48 h of follow-up was performed before sacrifice. Results: Median superoxide dismutase activities of liver tissue in Groups 3 and 4 were significantly higher than in Group 1 (for both, P = 0.001). The catalase activity in Group 2 was significantly higher, but in Groups 3 and 4 it was significantly lower than in Group 1 (for all, P = 0.001). The glutathione peroxidase activities in Groups 2, 3, and 4 were significantly higher than in Group 1 (P = 0.006, P = 0.001, and P = 0.001, respectively).
  • Particularly Hazardous Substances (Phs)

    Particularly Hazardous Substances (Phs)

    PARTICULARLY HAZARDOUS SUBSTANCES (PHS) This list contains examples of chemicals that may be used at the University of Nebraska Medical Center (UNMC). The list is not all-inclusive. This lists contains examples of Particularly Hazardous Substances (PHS) which are a special subset of OSHA Hazardous Chemicals. PHS include chemicals that are known or suspect carcinogens, reproductive toxins, and/or highly toxic materials. Before working with any PHS, please determine if you have any of these and evaluate if additional protective work practices are needed. You should utilize the PHS Assessment Form to help in this evaluation. Abbreviations Used in List Headings CARC NTP National Toxicology Program listed carcinogen - National Toxicology Program K = known carcinogen S = suspect carcinogen CARC IARC International Association for Research on Cancer listed carcinogen - IARC 1= known human carcinogen 2A = probable human carcinogen 2B = possible human carcinogen CARC OSHA OSHA regulated carcinogen - OSHA-regulated carcinogens X = regulated carcinogen REPRO SHEP Included in Catalog of Teratogenic Agents, T.H. Shepard, 6th Edition, Johns Hopkins Press, 1989 X = listed teratogen REPRO CALIF Listed by the State of California ‘Safe Drinking Water Act, 1986’ http://www.oehha.ca.gov/prop65/prop65_list/Newlist.html F = female reproductive hazard M = male reproductive hazard HTX Highly toxic, included in EPA’s list ‘Acutely Toxic Hazardous Waste’, P-listed waste 40 CFR 261.33, or Included in OSHA’s list of highly hazardous chemicals with a threshold £200